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SUMMARY
On February 24, 2010, a 13-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV13 [Prevnar 13, Wyeth 
Pharmaceuticals Inc., marketed by Pfizer Inc.]) was licensed by the Food and Drug Administration (FDA) for prevention of 
invasive pneumococcal disease (IPD) caused among infants and young children by the 13 pneumococcal serotypes covered by the 
vaccine and for prevention of otitis media caused by serotypes also covered by the 7-valent pneumococcal conjugate vaccine for-
mulation (PCV7 [Prevnar, Wyeth]). PCV13 contains the seven serotypes included in PCV7 (serotypes 4, 6B, 9V, 14, 18C, 19F, 
and 23F) and six additional serotypes (serotypes 1, 3, 5, 6A, 7F, and 19A). PCV13 is approved for use among children aged 6 
weeks–71 months and supersedes PCV7, which was licensed by FDA in 2000. 
This report summarizes recommendations approved by the Advisory Committee on Immunization Practices (ACIP) on February 
24, 2010, for the use of PCV13 to prevent pneumococcal disease in infants and young children aged <6 years. Recommendations 
include 1) routine vaccination of all children aged 2–59 months, 2) vaccination of children aged 60–71 months with underlying 
medical conditions, and 3) vaccination of children who received ≥1 dose of PCV7 previously (CDC. Licensure of a 13-valent 
pneumococcal conjugate vaccine [PCV13] and recommendations for use among children—Advisory Committee on Immunization 
Practices [ACIP], 2010. MMWR 2010;59:258–61). Recommendations also are provided for targeted use of the 23-valent pneu-
mococcal polysaccharide vaccine (PPSV23, formerly PPV23) in children aged 2–18 years with underlying medical conditions that 
increase their risk for contracting pneumococcal disease or experiencing complications of pneumococcal disease if infected. 
The ACIP recommendation for routine vaccination with PCV13 and the immunization schedules for children aged ≤59 months 
who have not received any previous PCV7 or PCV13 doses are the same as those published previously for PCV7 (CDC. Preventing 
pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices 
[ACIP]. MMWR 2000;49[No. RR-9]; CDC. Updated recommendation from the Advisory Committee on Immunization Practices 
[ACIP] for use of 7-valent pneumococcal conjugate vaccine [PCV7] in children aged 24–59 months who are not completely vac-
cinated. MMWR 2008;57:343–4), with PCV13 replacing PCV7 for all doses. For routine immunization of infants, PCV13 
is recommended as a 4-dose series at ages 2, 4, 6, and 12–15 months. Infants and children who have received ≥1 dose of PCV7 
should complete the immunization series with PCV13. A single supplemental dose of PCV13 is recommended for all children 
aged 14–59 months who have received 4 doses of PCV7 or another age-appropriate, complete PCV7 schedule. For children who 
have underlying medical conditions, a supplemental PCV13 dose is recommended through age 71 months. Children aged 2–18 
years with underlying medical conditions also should receive PPSV23 after completing all recommended doses of PCV13.
Introduction
Streptococcus pneumoniae (pneumococcus) remains a lead-
ing cause of serious illness, including bacteremia, meningitis, 
and pneumonia among children and adults worldwide. It is 
also a major cause of sinusitis and acute otitis media (AOM). 
In February 2000, a 7-valent pneumococcal polysaccharide-
protein conjugate vaccine (PCV7; Prevnar, Wyeth) was licensed 
by the Food and Drug Administration (FDA) for use among 
infants and young children in the United States (1). In pre-
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licensure randomized clinical trials, PCV7 was demonstrated 
to be safe and highly efficacious against invasive pneumococ-
cal disease (IPD), moderately efficacious against pneumonia, 
and somewhat effective in reducing otitis media episodes and 
related office visits (2–4). On the basis of the results of these 
clinical trials, in 2000, ACIP recommended routine use of 
PCV7 for all children aged 2–23 months and for children aged 
24–59 months who are at increased risk for pneumococcal 
disease (e.g., children with anatomic or functional asplenia, 
sickle cell disease (SCD), HIV infection or other immunocom-
promising condition, or chronic illness including chronic heart 
or lung disease, cerebrospinal fluid leaks, and diabetes mellitus) 
(1). In 2007, ACIP revised its recommendation for routine 
use to include all children aged 2–59 months (5). National 
Immunization Survey data indicate that in 2009, PCV7 cov-
erage among children aged 19–35 months was 92.6% for ≥3 
doses and 80.4% for ≥4 doses (6).
The safety, efficacy, and effectiveness in practice of PCV7 
and other pneumococcal conjugate vaccines has been estab-
lished in multiple settings in both industrialized and develop-
ing countries (7). In 2007, the World Health Organization 
(WHO) recommended that all countries incorporate pneumo-
coccal conjugate vaccines in their national infant immunization 
programs (8). 
On February 24, 2010, a new 13-valent pneumococcal 
polysaccharide-protein conjugate vaccine (PCV13 [Prevnar13], 
Wyeth Pharmaceuticals, Inc., marketed by Pfizer, Inc.) was 
approved by FDA for prevention of IPD caused among infants 
and young children by the 13 serotypes in the vaccine (9). 
PCV13 is formulated and manufactured using the same pro-
cesses as PCV7 and was licensed by FDA on the basis of stud-
ies demonstrating safety and an ability comparable to that of 
PCV7 to elicit antibodies protective against IPD (10). PCV13 
is approved for use among children aged 6 weeks–71 months 
and replaces PCV7, which is made by the same manufacturer. 
PCV13 contains the seven serotypes included in PCV7 (sero-
types 4, 6B, 9V, 14, 18C, 19F, and 23F) and six additional 
serotypes (1, 3, 5, 6A, 7F, and 19A). PCV13 also is approved 
for the prevention of otitis media caused by the seven serotypes 
also covered by PCV7; no efficacy data for prevention of otitis 
media are available for the six additional serotypes.
This report summarizes the recommendations approved by 
ACIP on February 24, 2010, for the prevention of pneumococ-
cal disease among infants and children aged ≤18 years (11) and 
replaces the previous ACIP recommendations for preventing 
pneumococcal disease in children (1,5,12). It also provides 
updated information regarding changes in the epidemiology 
of pneumococcal disease in the United States after the routine 
PCV7 infant vaccination program began in 2000. 
Background
Clinical Efficacy of Pneumococcal 
Conjugate Vaccines
The efficacy of pneumococcal conjugate vaccines (PCVs) 
was evaluated in randomized, controlled trials among children 
aged <2 years. A prelicensure clinical efficacy trial of PCV7 con-
ducted among 37,868 healthy children at a health maintenance 
organization in northern California indicated that PCV7 was 
97.4% (95% confidence interval [CI] = 82.7%–99.9%) effica-
cious against IPD caused by vaccine serotypes (the primary end-
point) among fully vaccinated infants (2). A recently updated 
systematic review by the Cochrane Collaboration included 
results from five randomized, controlled trials to evaluate PCVs 
(including PCV7 and experimental 9-valent and 11-valent vac-
cine formulations) against IPD and/or pneumonia. The trials 
conducted in various settings in both industrialized countries 
(U.S. general population [2] and Native American children 
[13]) and developing countries (South Africa [14], the Gambia 
[15], and the Philippines [16]) included 113,044 children aged 
<2 years (17). PCVs were demonstrated to be efficacious in 
preventing IPD, X-ray–confirmed pneumonia, and clinically 
diagnosed pneumonia. Among healthy children aged <2 years, 
the pooled PCV vaccine efficacy estimate was 80% (95% CI = 
58%–90%) for vaccine-type IPD, 58% (95% CI = 29%–75%) 
for IPD caused by all serotypes, 27% (95% CI = 15%–36%) 
for chest X-ray–confirmed pneumonia meeting WHO criteria 
(18), and 6% (95% CI = 2%–9%) for clinical pneumonia.
In a clinical trial conducted in South Africa, a 9-valent 
investigational PCV was administered to infants as a 3-dose 
schedule at age 6, 10, and 14 weeks without a booster dose. 
This vaccine prevented IPD among HIV-infected children, 
although the point estimate was somewhat lower (65%; 95% 
CI = 24%–86%) than among HIV-uninfected children (83%; 
95% CI = 39%–97%) (14). After a 6-year follow-up, vaccine 
efficacy against IPD declined substantially among HIV-infected 
children but not among healthy children (19).
Before PCV7 introduction, Streptococcus pneumoniae was 
detected in 28%–55% of middle-ear aspirates among children 
with AOM (1). In a randomized, clinical trial conducted in 
Finland in which the bacterial etiology of AOM was deter-
mined by myringotomy, the efficacy of PCV7 in preventing 
culture-confirmed, vaccine serotype AOM episodes was 57% 
(95% CI = 44%–67%) (4); the overall net reduction in AOM 
caused by any pneumococcal serotype was 34% (95% CI = 
21%–45%). Overall, PCV7 prevented 6%–7% of all AOM 
episodes in the clinical trials (2,4,20); reductions also were 
observed for the outcomes of frequent otitis media (9%) and 
tympanostomy tube placement (20%) (2). 
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FIGURE 1. Incidence* of invasive pneumococcal disease (IPD) 
among children aged <18 years, by age group — United States, 
Active Bacterial Core surveillance areas, 1998–1999 and 2008
*Per 100,000 population.
Updated Safety Data from PCV7 
Postmarketing Studies
A systematic review of 42 pre- and postmarketing infant 
studies did not identify major safety problems with PCV7 or 
other PCVs (21). In general, PCV7 injection-site reactions 
were mild and self-limited. The incidence of high fever was 
<1%. Mild local and systemic reactions were sometimes more 
frequent after the second and third vaccination than after the 
first vaccination. A small increase in hospitalizations for reactive 
airway disease was observed among PCV7 and PCV9 recipi-
ents compared with controls in two large clinical trials (2,14). 
However, a 3-year follow-up study of safety outcomes among 
subjects in the U.S. IPD efficacy study did not demonstrate an 
association of PCV7 with increased health-care use for reactive 
airway disease (22).
According to data from the Vaccine Adverse Event Reporting 
System (VAERS), a U.S. passive reporting system for adverse 
events occurring after immunization, the majority of reports 
received during the first 2 years after PCV7 licensure among 
children were minor adverse events similar to those observed 
previously in prelicensure clinical trials (23). Approximately 
31.5 million PCV7 doses were distributed during this time 
period, and VAERS received 4,154 reports of events that had 
occurred within 3 months of receiving PCV7 (rate: 13 reports 
per 100,000 PCV7 doses distributed). In 74.3% of reports, 
the child had received other vaccines concurrently with PCV7. 
Serious events were described in 608 (14.6%) reports, con-
sistent with the frequency of serious adverse events (14.2%) 
reported to VAERS for other childhood vaccines (24). 
Epidemiology of Pneumococcal 
Disease Among Children Aged 
<5 Years After Routine PCV7 
Immunization
Invasive Pneumococcal Disease
Effectiveness data from observational postmarketing studies 
of the U.S. routine infant PCV7 immunization program have 
been consistent with the results of prelicensure randomized 
clinical trials (25–29). In the United States, major changes 
have occurred in the epidemiology of pneumococcal disease 
after routine infant vaccination with PCV7 began in 2000 
(7,30). Substantial decreases were observed in the incidence 
rates of invasive pneumococcal disease, including pneumococ-
cal meningitis (31,32) among young children.
Data from the Active Bacterial Core Surveillance [ABCs], 
an active population- and laboratory-based surveillance system 
(http://www.cdc.gov/abcs/index.html) indicate that the overall 
incidence of IPD among children aged <5 years decreased 
from approximately 99 cases per 100,000 population dur-
ing 1998–1999 to 21 cases per 100,000 population in 2008 
(rate difference: 78 cases per 100,000 population; percentage 
reduction: 79%) (Figure 1) (CDC, unpublished data, 2009). 
The reductions in overall IPD resulted from a 99% decrease 
in disease caused by the seven serotypes in PCV7 and serotype 
6A, a serotype against which PCV7 provides some cross-
protection (28). The decreases have been offset partially by 
increases in IPD caused by nonvaccine serotypes, in particular 
19A (33,34). In the general U.S. population, the overall rates 
of IPD have leveled off and remained at approximately 22–25 
annual cases per 100,000 children aged <5 years since 2002 
(34). Although the absolute rate increase in IPD attributable 
to 19A in the general population has been small (approxi-
mately five cases per 100,000 population) compared with the 
decreases in PCV7-type disease (35–37), surveillance of one 
small population (Alaska Native children living in a remote 
region) showed a reduced overall vaccine benefit because of 
an increase in IPD caused by non-PCV7 types, particularly 
serotype 19A (38,39). 
trends in Antimicrobial Resistance
The emergence of pneumococcal strains resistant to 
penicillin and other antibiotics complicates the treatment of 
pneumococcal disease and might reduce the effectiveness of 
recommended treatment regimens. Before PCV7 was intro-
duced, five of the seven serotypes included in PCV7 (6B, 
9V, 14, 19F, and 23F) accounted for approximately 80% of 
penicillin-nonsusceptible isolates (1). Following routine PCV7 
use, the incidence of IPD caused by penicillin-resistant strains 
decreased 57% overall and 81% among children aged <2 
years. These decreases were a result of declines in nonsuscep-
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FIGURE 2. Proportion of cases of invasive pneumococcal disease 
among children aged <5 years, by vaccine serotype — United 
States, Active Bacterial Core surveillance areas, 2008
Abbreviation: PCV7 = 7-valent pneumococcal polysaccharide-protein conju-
gate vaccine.
tible PCV7 serotypes. (40). Decreases also were observed for 
erythromycin-resistant strains and those resistant to multiple 
antibiotics. However, IPD caused by penicillin-nonsusceptible 
non-PCV7 serotypes has increased, and most of the resistant 
infections now are caused by serotype 19A (33,35,37,40–42). 
In addition, the emergence of multidrug-resistant serotype 19A 
strains causing meningitis and other severe invasive infections 
(31,43), pneumococcal mastoiditis (44), and treatment failures 
for otitis media have been reported (45). 
trends in noninvasive Pneumococcal 
Disease
Decreases in rates of hospitalizations and ambulatory care 
visits for community-acquired pneumonia have been reported 
consistently among children aged <2 years after PCV7 intro-
duction (46–49). From pre-PCV7 baseline (1997–1999) to 
2006, the rate of hospitalizations for pneumonia attributable 
to all causes decreased 35% (from 12.5 to 8.1 cases per 1,000 
population) among children aged <2 years (46). Compared 
with the average annual number of pneumonia admissions dur-
ing 1997–1999, this rate reduction represented an estimated 
36,300 fewer pneumonia hospitalizations in 2006, when an 
estimated 67,400 total hospitalizations for all causes of pneu-
monia occurred among children aged <2 years in the United 
States. No similar reduction in pneumonia hospitalizations 
has been observed in children aged 2–4 years. 
 An estimated 13 million episodes of AOM occur annually 
in the United States among children aged <5 years (50,51). 
Population-based studies using various national and regional 
administrative and insurance databases have reported decreases 
in rates of ambulatory visits for otitis media (52,53), rates of 
frequent otitis media (defined as three episodes in 6 months 
or four episodes in 1 year) and tympanostomy-tube placement 
(54) among young children following PCV7 introduction. 
Although the observed trends in health-care use for otitis media 
might have been affected by factors other than PCV7 (e.g., 
secular trend or changes in coding or clinical practices), even 
modest vaccine-associated reductions in otitis media would 
result in substantial health benefits because of the substantial 
burden of disease (51).
Indirect Effects of the PCV7 
Vaccination Program in Unvaccinated 
Populations
Substantial evidence has accumulated to demonstrate that 
routine infant PCV7 vaccination has reduced transmission 
of PCV7 serotypes, resulting in a reduced incidence of IPD 
among unvaccinated persons of all ages, including infants too 
young to be vaccinated and elderly persons (7,27,30,55,56). 
Among persons aged 18–49 years, 50–64 years, and ≥65 years, 
overall rates of IPD have decreased 34%, 14%, and 37% 
respectively from 1998–1999 to 2008; decreases in rates of 
disease caused by PCV7 serotypes ranged from 90% to 93% 
(CDC, unpublished data, 2009).
The measured indirect effects on noninvasive pneumococcal 
disease have been less clear (49). However, a time-series analysis 
of national hospital discharge data during 1997–2004 indi-
cated a statistically significant decrease after PCV7 introduction 
in rates of all-cause pneumonia hospitalizations among young 
adults but not among other adult age groups (47). 
Invasive Pneumococcal Disease 
Caused by Serotypes Covered in 
PCV13 
ABCs data indicate that in 2008, a total of 61% of IPD 
cases among children aged <5 years were attributable to the 
serotypes covered in PCV13, with serotype 19A accounting 
for 43% of cases; PCV7 serotypes caused <2% of cases (Figure 
2). Three of the six additional serotypes, (19A, 7F, and 3) 
accounted for 99% of IPD cases, serotypes 1 and 5 together 
caused 0.6% of cases, and serotype 6A caused 0.6% of cases. 
In age groups ≥5 years, the serotypes covered in PCV7 caused 
from 4% to 7%, and the serotypes in PCV13 caused 43%–66% 
of IPD cases, respectively (Figure 3). 
 In 2008, children aged <24 months accounted for more 
than two thirds of all IPD cases among children aged <5 years; 
overall rates were highest among children aged <12 months and 
12–24 months (rate: 39 and 32 cases per 100,000 population, 
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TABLE 1. Rates* of invasive pneumococcal disease (IPD) among children aged <5 years, by age, race, and vaccine serotype group, — 
Active Bacterial Core surveillance (ABCs),† 10 U.S. sites, 2008
Serotype group
Age (yrs)
All  races White Black
All IPD
PCV13  
types
Non-PCV13 
types All IPD
PCV13  
types
Non-PCV13 
types All IPD
PCV13
types
Non-PCV13 
types
<1 39.2 23.8 15.5 33.3 20.3 13.0 65.6 40.0 25.6 
1 32.4 15.9 16.5 27.9 13.7 14.2 47.4 23.2 24.2 
2 12.6 8.8 —§ 7.1 5.0  — 28.0 19.4  — 
3 10.8 7.3 — 6.6 4.5  — 24.0 16.3  — 
4 9.2 7.7 — 9.8 8.1  —  —  —  — 
All <5 21.0 12.7 8.2 17.0 10.3 6.7 34.9 21.2 13.7 
Abbreviation: PCV13 = 13-valent pneumococcal polysaccharide-protein conjugate vaccine.
Source: CDC, Active Bacterial Core surveillance (ABCs), unpublished data, 2009.  
* Per 100,000 population.
† Information about ABCs is available at http://www.cdc.gov/abcs/index.html.
§ Indicates too few cases in the cell to calculate rates. For races other than black and white, the number of cases was too low to calculate rates in individual 
1-year age strata. Among children of other races aged <5 years, overall rates were 14.6 for all IPD, 8.9 for PCV13 types, and 5.7 for non-PCV13 types.
Children at Increased Risk for 
Pneumococcal Infections
Rates of pneumococcal infections in the United States 
vary among demographic groups, with higher rates occur-
ring among infants, young children, elderly persons, Alaska 
Natives, and certain American Indian populations. Although 
racial disparities have diminished since PCV7 was introduced 
(57,58), black children continue to have higher rates of IPD 
compared with white children (Table 1). The risk for IPD 
is highest among persons who have congenital or acquired 
immunodeficiency, abnormal innate immune response, HIV-
infection, or absent or deficient splenic function (e.g., SCD or 
congenital or surgical asplenia) (1,12). Children with cochlear 
implants are also at substantially increased risk for pneumococ-
cal meningitis (59,60).
 Several studies have evaluated antibody responses to PCV7 
among children with SCD and among HIV-infected children 
(1,61). The antibody responses among infants with SCD gener-
ally have been comparable to infants without SCD (62–64). 
For HIV-infected children, the antibody responses to various 
PCV formulations have been slightly lower but generally are 
comparable to those in HIV-uninfected children (65,66). 
Studies of small numbers of children with SCD and HIV 
infection suggested that PCV7 is safe and immunogenic when 
administered to children aged ≤13 years (1,65). In addition, a 
multicenter study indicated that a schedule of 2 doses of PCV7 
followed by 1 dose of 23-valent pneumococcal polysaccharide 
vaccine (PPSV23, formerly PPV23) was safe and immunogenic 
in highly active antiretroviral therapy (HAART)–treated HIV-
infected children and adolescents aged 2–19 years who had 
not received PCV7 in infancy (however, 75% of subjects had 
received PPSV23 previously) (67). In addition, PCV7 was as 
respectively) (Table 1). Among children aged >24 months, 
rates decreased markedly with age. Rates of all IPD and IPD 
caused by serotypes covered by PCV13 were twice as high in 
black children as in white children. However, no difference was 
found between the proportion of IPD cases caused by PCV13 
serotypes in black children compared with white children 
(CDC, unpublished data, 2009). 
Projections from active surveillance data to the U.S. 
population indicate that in 2008, an estimated 4,100 cases of 
IPD (rate: 20 cases per 100,000 population) occurred among 
children aged <5 years in the United States; PCV13 serotypes 
caused an estimated 2,500 cases (rate: 12 cases per 100,000 
population) (CDC, unpublished data, 2009). 
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TABLE 2. Underlying medical conditions that are indications for pneumococcal vaccination among children, by risk group
Risk group Condition
Immunocompetent children Chronic heart disease*
Chronic lung disease†
Diabetes mellitus 
Cerebrospinal fluid leaks
Cochlear implant
Children with functional or anatomic 
asplenia
Sickle cell disease and other hemoglobinopathies
Congenital or acquired asplenia, or splenic dysfunction
Children with immunocompromising 
conditions
HIV infection
Chronic renal failure and nephrotic syndrome
Diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant 
neoplasms, leukemias, lymphomas and Hodgkin disease; or solid organ transplantation
Congenital immunodeficiency§
Source: Advisory Committee on Immunization Practices, 2010.
* Particularly cyanotic congenital heart disease and cardiac failure.
† Including asthma if treated with high-dose oral corticosteroid therapy.
§ Includes B- (humoral) or T-lymphocyte deficiency; complement deficiencies, particularly C1, C2, C3, and C4 deficiency; and phagocytic disorders (excluding chronic 
granulomatous disease).
immunogenic among low birth weight and preterm infants as 
among normal birth weight and full-term infants (68). 
 After the introduction and widespread use of HAART in 
the United States, rates of IPD among HIV-infected children 
decreased, but whether further declines have occurred after 
routine PCV7 vaccination is unclear, and rates remain elevated 
compared with those for HIV-uninfected children (69). Rates 
among children with SCD have decreased substantially follow-
ing PCV7 introduction but still remain higher than among 
healthy children, particularly among older children with SCD 
(70,71). 
 During 2006–2008, of 475 IPD cases in children aged 
24–59 months in the ABCs surveillance population of approxi-
mately 18 million persons, 51 (11%) cases occurred in children 
with underlying medical conditions that are indications for 
PPSV23 (Table 2). Of these 51 cases, 23 (45%) were caused 
by PCV13 serotypes (Table 3). The 11 serotypes included 
in PPSV23 but not in PCV13 (serotype 6A is not included 
in PPSV23) caused an additional eight (16%) cases (CDC, 
unpublished data, 2009).
13-Valent Pneumococcal Conjugate 
Vaccine
Vaccine Composition
PCV13 (Prevnar13) contains polysaccharides of the cap-
sular antigens of S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 
7F, 9V, 14, 18C, 19A, 19F, and 23F, individually conjugated 
to a nontoxic diphtheria cross-reactive material (CRM) carrier 
protein (CRM197). A 0.5-mL PCV13 dose contains approxi-
mately 2.2 μg of polysaccharide from each of 12 serotypes and 
approximately 4.4 μg of polysaccharide from serotype 6B; the 
total concentration of CRM197 is approximately 34 μg. The 
vaccine contains 0.02% polysorbate 80 (P80), 0.125 mg of 
aluminum as aluminum phosphate (AlPO4) adjuvant, 5mL 
of succinate buffer, and no thimerosal preservative (9). Except 
for the addition of six serotypes, P80, and succinate buffer, the 
formulation of PCV13 is the same as that of PCV7.
Evaluation of PCV13 Immunogenicity
The immunogenicity of PCV13 was evaluated in a random-
ized, double-blind trial (Study 004) in which 663 healthy U.S. 
infants received at least 1 dose of PCV13 or PCV7 according 
to the routine immunization schedule (at ages 2, 4, 6, and 
12–15 months) (10). To compare PCV13 antibody responses 
with those for PCV7, criteria for noninferior immunogenicity 
after 3 and 4 doses of PCV13 (pneumococcal IgG antibody 
concentrations measured by enzyme-linked immunosorbent 
assay [ELISA]) were defined for the seven serotypes common 
to PCV7 and PCV13 and for the six additional serotypes in 
PCV13. Functional antibody responses were evaluated by 
opsonophagocytosis assay in a subset of the study population 
(10). Evaluation of these immunologic parameters indicated 
that PCV13 induced levels of antibodies that were comparable 
to those induced by PCV7 and shown to be protective against 
IPD (10). PCV13 immunogenicity data are not yet available 
for children in the specific groups at increased risk for pneu-
mococcal disease.
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TABLE 3. Number and proportion of children aged 24–59 months with invasive pneumococcal disease (IPD), by PPSV23 indication and sero-
type group — Active Bacterial Core Surveillance (ABCs), 10 U.S. sites, 2006–2008 
 Serotype Group
All IPD PCV13
Serotypes included 
in PPSV23 but not in 
PCV13* Other serotypes Unknown serotypes
No. No. (%) No. (%) No. (%) No. (%) 
All Cases 475 276 58.1 73 15.4 54 11.4 72 15.2
No underlying condition† 424 253 59.7 65 15.3 40 9.4 66 15.6
Any ACIP indication 51 23 45.1 8 15.7 14 27.5 6 11.8
Sickle cell disease or asplenia§ 11 3 27.3 3 27.3 5 45.5 0 0
HIV/AIDS 0 0 0 0 0 0 0 0 0
Chronic illness¶ 3 1 33.3 0 0 1 33.3 1 33.3
Other immunocompromising condition¶ 37 19 51.4 5 13.5 8 21.6 5 13.5
Abbreviations: PPSV23 = 23-valent pneumococcal polysaccharide vaccine, PCV13 = 13-valent pneumococcal polysaccharide-protein conjugate vaccine, and ACIP = 
Advisory Committee on Immunization Practices.
* The 11 serotypes included in PPSV23 but not in PCV13; serotype 6A is not included in PPSV23. 
† Absence of underlying medical conditions listed in Table 2.
§ Includes other hemoglobinopathies, congenital or acquired asplenia, or splenic dysfunction.
¶ Does not include HIV, AIDS, sickle cell disease, hemoglobinopathies, or splenic dysfunction.
Immune Responses After the 3-Dose Infant 
Series among Healthy Infants
Among infants receiving the 3-dose primary infant series, 
responses to ten of the PCV13 serotypes met the prespecified 
primary endpoint criterion (percentage of subjects achieving an 
IgG seroresponse of ≥0.35 μg/mL 1 month after the third dose) 
(72–74). Responses to shared serotypes 6B and 9V and new 
serotype 3 did not meet this criterion (Table 4). For serotypes 
6B and 9V, however, the differences were small. Among PCV13 
recipients, the IgG seroresponse rate for serotype 3 was 63.5%; 
for the other additional serotypes, the seroresponse rate ranged 
from 89.7% (serotype 5) to 98.4% (serotypes 7F and 19A). 
Detectable opsonophygocytic antibodies (OPA) to serotypes 
6B, 9V, and 3 indicated the presence of functional antibodies 
(74,75). The percentages of subjects with an OPA antibody 
titer ≥1:8 were similar for the seven common serotypes among 
PCV13 recipients (range: 90%–100%) and PCV7 recipients 
(range: 93%–100%); the proportion of PCV13 recipients 
with an OPA antibody titer ≥1:8 was >90% for all of the 13 
serotypes (10). 
Immune Responses After the Fourth Dose 
Among Healthy Children
After the fourth dose, the noninferiority criterion for IgG 
geometric mean concentrations (GMCs) was met for 12 of 
the 13 serotypes; the noninferiority criterion was not met for 
the response to serotype 3 (Table 5). For the seven common 
serotypes, the IgG GMCs achieved after the 4-dose series were 
somewhat lower for PCV13 than for PCV7, except for serotype 
19F (Table 5). Detectable OPA antibodies were present for 
all serotypes after the fourth dose; the percentage of PCV13 
recipients with an OPA titer ≥1:8 ranged from 97% to 100% 
for the 13 serotypes and was 98% for serotype 3. Following 
the fourth dose, the IgG GMCs and OPA geometric mean 
titers (GMTs) were higher for all 13 serotypes compared with 
those after the third dose. 
Antibody Responses to PCV13 Booster Dose 
Among toddlers Who Received 3 Doses of 
Either PCV7 or PCV13 as Infants
In a randomized, double-blind trial conducted in France, 
613 infants were randomly assigned to three groups in a 2:1:1 
ratio: 1) PCV13 at ages 2, 3, 4, and 12 months [PCV13/
PCV13] or 2) PCV7 at ages 2, 3, and 4 months followed 
by PCV13 at age 12 months [PCV7/PCV13] or 3) PCV7 
at ages 2, 3, 4, and 12 months [PCV7/PCV7] (Study 008) 
(10). A single PCV13 dose administered at age 12 months to 
children who had received 3 doses of PCV7 resulted in higher 
IgG GMCs to all six additional serotypes compared with IgG 
GMCs after 3 PCV13 doses administered to infants at 2, 3, 
and 4 months. One month after the 12-month dose, the IgG 
GMCs for the seven common serotypes were similar among 
all three groups. For five of the six additional serotypes, IgG 
GMCs among PCV7/PCV13 recipients were somewhat lower 
than among PCV13/PCV13 recipients; for serotype 3, GMC 
was somewhat higher among the PCV7/PCV13 group (Table 
6). The clinical relevance of these lower antibody responses is 
not known (9).
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TABLE 4. Percentage of infants with pneumococcal IgG ≥0.35 μg/mL 1 month following the third infant dose — noninferiority study (004), 
United States
Vaccine serotype PCV13 (n† = 249–252) PCV7 (n = 250–252) Difference* (%PCV13 - PCV7)
95% CI for the difference in 
proportions
Common serotypes
4 94.4 98.0 -3.6 (-7.3– -0.1)
6B§ 87.3 92.8 -5.5 (-10.9– -0.1)
9V§ 90.5 98.4 -7.9 (-12.4– -4.0)
14 97.6 97.2 0.4 (-2.7–3.5)
18C 96.8 98.4 -1.6 (-4.7–1.2)
19F 98.0 97.6 0.4 (-2.4–3.4)
23F 90.5 94.0 -3.6 (-8.5–1.2)
6 additional serotypes in PCV13
1 95.6 ¶ 2.8 (-1.3–7.2)
3§ 63.5 ¶ -29.3 (-36.2–22.4)
5 89.7 ¶ -3.1 (-8.3–1.9)
6A 96.0 ¶ 3.2 (-0.8–7.6)
7F 98.4 ¶ 5.6 (1.9–9.7)
19A 98.4 ¶ 5.6 (1.9–9.7)
Abbreviations: PCV13 = 13-valent pneumococcal polysaccharide-protein conjugate vaccine, PCV7 = 7-valent pneumococcal polysaccharide-protein conjugate vac-
cine, and CI = confidence interval.
Source: Food and Drug Administration clinical review of PCV13 (10). 
* Difference in proportions (PCV13-PCV7 reference value) expressed as a difference in percentages. 
† N = range of subjects with a determinate IgG antibody concentration by enzyme-linked immunosorbent assay (ELISA) to a given serotype.
§ Serotype did not meet the prespecified primary endpoint criterion.
¶ For the additional serotypes, the reference value is serotype 6B in the PCV7 group. Noninferiority was defined as the lower limit of the 2-sided 95% CI for the difference 
in proportions of >-10%.
TABLE 5. Pneumococcal IgG geometric mean concentrations (μg/mL) 1 month following the fourth (booster) dose of pneumococcal conju-
gate vaccine, noninferiority study (004), United States 
Vaccine serotype PCV13 (n† = 232–236) PCV7 (n = 222–223) GMC ratio* (PCV13/PCV7) 95% CI for the GMC ratio
Common serotypes
4 3.7 5.5 0.7 (0.6–0.8)
6B 11.5 15.6 0.7 (0.6–0.9)
9V 2.6 3.6 0.7 (0.6–0.9)
14 9.1 12.7 0.7 (0.6–0.9)
18C 3.2 4.7 0.7 (0.6–0.8)
19F 6.6 5.6 1.2 (1.0–1.4)
23F 5.1 7.8 0.7 (0.5–0.8)
6 additional serotypes in PCV13
1 5.1 ¶ 1.4 (1.2–1.7)
3§ 0.9 ¶ 0.3 (0.2–0.3)
5 3.7 ¶ 1.0 (0.9–1.2)
6A 8.2 ¶ 2.3 (1.9–2.7)
7F 5.7 ¶ 1.6 (1.3–1.9)
19A 8.6 ¶ 2.4 (2.0–2.8)
Abbreviations: PCV13 = 13-valent pneumococcal polysaccharide-protein conjugate vaccine, PCV7 = 7-valent pneumococcal polysaccharide-protein conjugate 
vaccine, GMC = geometric mean concentrations, and CI = confidence interval.
Source: Food and Drug Administration clinical review of PCV13 (10). 
* GMC ratio: PCV13 to PCV7 reference. 
† N = range of subjects with a determinate IgG antibody concentration by enzyme-linked immunosorbent assay (ELISA) to a given serotype.
§ Serotype did not meet the prespecified noninferiority criteria.
¶ For the additional serotypes, the reference value is serotype 9V in the PCV7 group. Noninferiority was defined as a lower limit of the 2-sided 95% CI for the GMC 
ratio (PCV13 group/PCV7 group) >0.5.
 After the 12-month dose of PCV13, the percentage of 
children with OPA antibody titers ≥1:8 for the six additional 
serotypes were comparable regardless of whether the children 
had received PCV7 or PCV13 in infancy. The OPA GMTs 
among PCV7/PCV13 recipients also were similar to those 
among PCV13/PCV13 recipients (Figure 4) (Study 008) 
(10). 
Immune Responses Among Previously 
Unvaccinated older Infants and Children
In an open-label, nonrandomized and noncontrolled study 
of PCV13 conducted in Poland (Study 3002), children aged 
7–11 months, 12–23 months, and 24–71 months who had 
not received pneumococcal conjugate vaccine doses previ-
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TABLE 6. Pneumococcal IgG antibody geometric mean concentrations (μg/mL) 1 month after the 12-month dose among children pre-
viously administered 3 doses of either PCV13 or PCV7
Vaccine serotype
PCV13/PCV13  
after dose at 12 mos*  
(n† = 233–236)
PCV7/PCV13  
after dose at 12 mos*  
(n = 108–113)
PCV7/PCV7  
after dose at 12 mos*  
(n = 111–127)
Serotypes common to PCV7 and PCV13
4 4.2 4.0 4.9
6B 9.0 10.3 9.6
9V 2.6 2.3 3.2
14 9.5 7.8 10.8
18C 2.3 2.4 2.8
19F 5.2 3.7 4.1
23F 3.0 3.1 3.7
Six additional serotypes in PCV13
1 4.1 1.8 NA
3 1.0 1.3 NA
5 3.3 1.1 NA
6A 6.1 2.6 NA
7F 4.5 3.7 NA
19A 9.5 5.3 NA
Abbreviations: PCV13 = 13-valent pneumococcal polysaccharide-protein conjugate vaccine, PCV7 = 7-valent pneumococcal polysaccharide-protein conju-
gate vaccine, and NA = not applicable.
* A randomized, controlled trial conducted in France using a 3-dose infant series given at age 2, 3, 4 months and a toddler dose at age 12 months (Study 008). 
Data are from the Food and Drug Administration PCV13 clinical review (10).
† N = range of subjects with a determinate IgG antibody concentration by enzyme-linked immunosorbent assay (ELISA) to a given serotype.
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FIGURE 4. Opsonophygocytic antibody (OPA) responses (GMTs) to 
six additional serotypes after 4 doses of PCV13 and 3 doses of PCV7 
followed by 1 dose of PCV13* 
Abbreviations: PCV7 = 7-valent pneumococcal polysaccharide-protein conju-
gate vaccine, PCV13 = 13-valent pneumococcal polysaccharide-protein con-
jugate vaccine, 
Source: Food and Drug Administration. PCV13 clinical review (10).
*In both groups, the proportion of subjects with OPA titers ≥1:8 was ≥97.8%.
ously were administered 1, 2, or 3 doses of PCV13 according 
to age-appropriate immunization schedules (10). Descriptive 
analyses suggest that these three schedules resulted in antibody 
responses to each of the 13 serotypes that were comparable 
to the IgG GMCs achieved after the 3-dose infant PCV13 
series in the U.S. immunogenicity trial (Study 004), except 
for serotype 1, for which IgG GMC was lower among chil-
dren aged 24–71 months (1.78 μg/mL compared with 2.03 
μg/mL) in the U.S. study (10). Compared with the immune 
responses after 4 doses of PCV13, the responses induced by 
the recommended catch-up schedules among children aged 
≥7 months might result in lower antibody concentrations for 
some serotypes The clinical relevance of these lower antibody 
responses is not known (9). 
Adverse Reactions After 
Administration of PCV13 in Clinical 
trials
The safety of PCV13 was assessed in 13 clinical trials in 
which approximately 15,000 doses were administered to 4,729 
healthy children aged 6 weeks–15 months using various 3-dose 
primary infant schedules (at ages 2, 4, and 6 months; 2, 3, 
and 4 months; and 6, 10, and 14 weeks) with a booster dose 
at 12–15 months, concomitantly with other routine pediatric 
vaccines. Three primary safety studies were conducted in the 
United States. In these studies, 1,908 children received at least 
1 dose of PCV13 concomitantly with routine U.S. pediatric 
vaccinations. The comparison group of 2,760 children received 
at least 1 dose of PCV7. Supportive data for safety outcomes 
were provided by a study among 354 children aged 7–71 
months, who received at least 1 dose of PCV13 (9). No safety 
or immunogenicity studies for PVC13 have been completed 
among infants born prematurely, children aged ≥72 months, or 
children who have underlying medical conditions that increase 
the risk for pneumococcal disease. 
The most commonly reported (in ≥20% of subjects) solic-
ited adverse reactions that occurred within 7 days after each 
dose of PCV13 were injection-site reactions, fever, decreased 
appetite, irritability, and increased or decreased sleep (9). The 
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TABLE 7. Reported frequencies of adverse events occurring in >1% 
of recipients following administration of PCV13 or PCV7 in 13 com-
bined clinical trials
Adverse event
%
PCV 13* PCV 7†
Injection-site reaction* (n = 4,729) (n = 2,760)
Pain/Tenderness  48.8 54.4
Erythema (any) 46.6 46.6
Induration/swelling 35.3 37.1
Erythema (>2.4 cm but <7.0 cm)
Infant series 4.6 4.5
Toddler dose 13.6 12.8
Older children (aged 2–5 yrs) 37.8 NA
Induration/swelling (>2.4 cm but <7.0 cm)
Infant series 7.4 6.2
Toddler dose 12.4 11.3
Older children (aged 2–5 yrs) 25.0 NA
Pain/tenderness interfering with movement  8.0 8.7
Irritability* 70.0 68.4
Drowsiness/increased sleep*  59.2 58.3
Decreased appetite* 38.7 48.0
Fever*  36.9 46.7
Restless sleep/Decreased sleep*  36.0 34.4
Fever >39º C* 5.3 7.4
Diarrhea 3.1 3.0
Vomiting  1.8 2.0
Rash  1.1 1.6
Abbreviations: PCV13 = 13-valent pneumococcal polysaccharide-protein 
conjugate vaccine, PCV7 = 7-valent pneumococcal polysaccharide-protein 
conjugate vaccine, and NA = data not available.
* Solicited adverse events from 13 combined clinical trials among healthy 
infants and children aged 6 weeks–16 months and 354 children aged 7–71 
months. Data were obtained daily for 4 or 7 days after each vaccination and 
represent the highest frequency after any dose in the infant series, the toddler 
dose, or a dose given to older children who had not received PCV previously. 
The frequencies of solicited adverse reactions after each vaccine dose in the 
series were similar and are available in the PCV13 package insert (9).
immunogenicity or safety: diphtheria, tetanus, acellular pertus-
sis, Haemophilus influenzae type b, inactivated poliomyelitis, 
rotavirus, hepatitis B, meningococcal serogroup C, measles, 
mumps, rubella, and varicella (9). PCV13 can be administered 
at the same time as other routine childhood vaccinations if 
administered in a separate syringe at a separate injection site. 
The safety and efficacy of concurrent administration of PCV13 
and PPV23 has not been studied, and concurrent administra-
tion is not recommended.
Precautions and Contraindications
Before administering PCV13, vaccination providers should 
consult the package insert for precautions, warnings, and 
contraindications (9). Vaccination with PCV13 is contrain-
dicated in persons known to have a severe allergic reaction 
(e.g., anaphylaxis) to any component of PCV13 or PCV7 or 
to any diphtheria toxoid-containing vaccine. Before PCV13 
administration, all precautions should be taken to prevent 
allergic or any other adverse reactions, including a review of 
the patient’s vaccination history for possible sensitivity to the 
vaccine or similar vaccines and for previous vaccination-related 
incidence and severity of solicited local reactions at the injection 
site (pain, tenderness, erythema, and induration/swelling) and 
solicited systemic reactions (irritability, drowsiness/increased 
sleep, decreased appetite, fever, and restless or decreased sleep) 
were similar in the PCV13 and PCV7 groups (Table 7). The 
frequency of adverse reactions was similar after each vaccine 
dose in the series and is described in the PCV13 package insert 
(9). The frequency of unsolicited adverse events was also similar 
in the two groups. The following unsolicited adverse events 
occurred in >1% of infants and toddlers: diarrhea, vomiting, 
and rash. Reactions occurring in <1% of infants and toddlers 
following PCV13 included crying, hypersensitivity reaction 
(including face edema, dyspnea, and bronchospasm), seizures 
(including febrile seizures), and urticaria or urticaria-like rash. 
The most commonly reported serious adverse events included 
bronchiolitis, gastroenteritis, and pneumonia. Serious adverse 
events reported following vaccination occurred among 8.2% 
of PCV13 recipients and 7.2% of PCV7 recipients. No sta-
tistically significant differences in types or rates of serious 
adverse events or unanticipated adverse events were identified 
(9). These data suggest that the safety profiles of PCV13 and 
PCV7 are comparable.
The safety of a supplemental dose of PCV13 was evaluated 
in an open-label study in which 284 healthy U.S. children 
aged 15–59 months who had received 3 or 4 doses of PCV7 
previously received 1 or 2 doses of PCV13; children aged 
15–23 months received 2 PCV13 doses, and children aged 
24–59 months received 1 PCV13 dose (9). The incidence 
and severity of solicited local reactions and systemic adverse 
reactions that occurred within 7 days after 1 dose of PCV13 
among children aged 15–59 months who had received 4 PCV7 
doses were comparable to those among children receiving their 
fourth dose of PCV13 (see Tables 7 and 8 in PCV13 package 
insert) (9).
Certain rare adverse events that were observed during PCV7 
postmarketing surveillance are included in the PCV13 pack-
age insert (9) although they were not observed in the PCV13 
clinical trials: hypotonic-hyporesponsive episode, apnea, ana-
phylactic/anaphylactoid reaction including shock, angioneu-
rotic edema, erythema multiforme, injection-site dermatitis, 
injection-site pruritus, injection-site urticaria, and lymphade-
nopathy localized to the region of the injection site. The causal 
relation of these events to vaccination is unknown.
Vaccine Administration
PCV13 is administered intramuscularly as a 0.5-mL dose 
and is available in latex-free, single-dose, prefilled syringes. 
PCV13 has been administered concurrently with vaccines 
containing the following antigens with no adverse effects on 
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TABLE 8. Recommended schedule for use of 13-valent pneumo-
coccal conjugate vaccine (PCV13) among previously unvaccinated 
infants and children by age at time of first vaccination
Age at first dose (mos)
Primary PCV13 
series* PCV13 booster dose†
2–6 3 doses 1 dose at 12–15 mos
7–11 2 doses 1 dose at 12–15 mos
12–23 2 doses NA
24–59 in healthy children 1 dose NA
24–71 in children with 
certain chronic diseases 
or immunocompromising 
conditions§
2 doses NA
Abbreviation: NA = not applicable
* Minimum interval between doses is 8 weeks except for children vaccinated 
at age <12 months, for whom minimum interval between doses is 4 weeks. 
Minimum age for administration of first dose is 6 weeks.
† Administered at least 8 weeks after the previous dose. 
§ See Table 2 for a complete list of conditions.
adverse reactions to determine the presence of any contraindi-
cation to vaccination with PCV13 and to allow an assessment 
of risks and benefits. 
Apnea following intramuscular vaccination has been 
observed in some infants born prematurely. Decisions about 
when to administer an intramuscular vaccine, including 
PCV13, to infants born prematurely should be based on con-
sideration of the individual infant’s medical status and potential 
benefits and possible risks of vaccination (9).
All vaccines can be administered to persons with minor 
acute illness (e.g. diarrhea or mild upper-respiratory tract infec-
tion with or without fever). Persons with moderate or severe 
acute illness should be vaccinated as soon as the acute illness 
has improved, after screening for contraindications.
Adverse events after receipt of any vaccine, even if it is 
not clear that the vaccine caused the adverse event, should 
be reported to the Vaccine Adverse Event Reporting System 
(VAERS). Two methods can be used to report to VAERS: 
1) online reporting through the secure VAERS internet site 
(https://vaers.hhs.gov) is encouraged; 2) a reporting form can 
be downloaded at http://vaers.hhs.gov/esub/index and sent 
via fax to 877-721-0366 or mailed to VAERS, P.O. Box 1100, 
Rockville, MD 20849 when completed. Providers can contact 
VAERS at telephone 1-800-822-7967 or by e-mail at info@
vaers.org to request a reporting form or obtain assistance in 
reporting. 
23-Valent Pneumococcal 
Polysaccharide Vaccine
The 23-valent pneumococcal polysaccharide vaccine 
(PPSV23) (Pneumovax23, marketed by Merck & Company, 
Inc.) was licensed in the United States in 1983 and contains 
23 capsular polysaccharide antigens of S. pneumoniae: 1, 2, 3, 
4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 
19A, 19F, 20, 22F, 23F, and 33F. One 0.5-mL dose of PPSV23 
contains 25 μg of each polysaccharide in isotonic saline solu-
tion with 0.25% phenol as a preservative. 
Since 1997, ACIP has recommended use of PPSV23 for 
persons aged ≥2 years who have certain underlying medical 
conditions (Table 2) (12). Children with these conditions are 
at increased risk for IPD and might have infections caused 
by a broader range of serotypes than healthy children (76). 
Therefore, since 2000, children aged ≥2 years with underly-
ing medical conditions have been recommended to receive 
PPSV23 after PCV7 (1). PPSV23 is not recommended to be 
used alone for this group of children because conjugate vaccines 
have several advantages over PPSV23, including immunologic 
priming and induction of immunologic memory, reduction 
in nasopharyngeal carriage of vaccine type pneumococci, 
likely greater effectiveness against serotypes currently causing 
most IPD, and evidence for effectiveness against noninvasive 
syndromes including nonbacteremic pneumonia and otitis 
media (61,77). 
Data regarding safety of PPSV23 when administered after 
PCV13 are not available. However, clinical experience of 
PPSV23 use since 1983 has not raised safety concerns, and 
the reported safety profile for PPSV23 in children appears 
similar to adults; the most common adverse reactions follow-
ing PPSV23 vaccination are mild local reactions (e.g., pain at 
the injection site, erythema, and swelling) that usually resolve 
within 48 hours of vaccination (12,78). Immunogenicity data 
on sequential vaccination with PCV13 followed by PPSV23 are 
not available, but studies on sequential vaccination with PCV7 
followed by PPSV23 have demonstrated that PPSV23 elicits 
robust booster responses for the seven serotypes in common 
with PCV7 (79). Limited and inconclusive data are available 
on the efficacy and effectiveness of PPSV23 among children 
with underlying medical conditions (78), and the clinical 
effectiveness of PPSV23 among children who have received 
PCV7 or PCV13 is unknown. No safety or immunogenicity 
data are available regarding the vaccine sequence of PPSV23 
followed by PCV13; limited safety and immunogenity data are 
available for PPSV23 followed by PCV7 among HIV-infected 
children and adolescents (67).
Few studies have evaluated the immunogenicity and safety 
of >1 dose of PPSV23 in children systematically (78,79). 
Recent studies evaluating immune responses elicited by 
PPSV23 among adults (80,81) have reported a concern that 
vaccination with unconjugated pneumococcal polysaccharide 
antigens might induce hyporesponsiveness (i.e., lower antibody 
response) on rechallenge with pneumococcal antigens, includ-
ing PCV7, although the clinical relevance of this immunologic 
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observation is unknown (79). No data are available to indicate 
whether administration of PPSV23 to children before or after 
PCV13 might result in hyporesponsiveness to subsequent 
doses of PCV13.
Recommendations for Use of 
PCV13 and PPSV23
ACIP recommends use of PCV13 for 1) all children aged 
2–59 months and 2) children aged 60–71 months with under-
lying medical conditions that increase their risk for pneumo-
coccal disease or complications (Table 2).
no Previous PCV7/PCV13 Vaccination
The ACIP recommendation for routine vaccination with •	
PCV13 and the vaccination schedules for infants and 
toddlers through age 59 months who have not received 
any previous PCV7 or PCV13 doses are the same as those 
previously published for PCV7 (Table 8) (1,5). PCV13 is 
recommended as a 4-dose series at ages 2, 4, 6, and 12–15 
months.
Infants Aged 2–6 Months
The primary infant series consists of 3 doses of PCV13. •	
Infants receiving their first dose at age ≤6 months should 
receive 3 doses of PCV13 at intervals of approximately 
8 weeks (the minimum interval is 4 weeks). The fourth 
(booster) dose is recommended at age 12–15 months and 
at least 8 weeks after the third dose (Table 8). 
Newborns should begin the schedule at age 2 months, •	
although the first dose can be administered as early as 6 
weeks. For prematurely born infants (i.e., <37 weeks’ ges-
tation) who are medically stable enough to be vaccinated, 
PCV13 should be administered at the recommended chron-
ologic age concurrent with other routine vaccinations.
Children Aged ≥7 Months
Healthy children aged 7–59 months who have not been •	
vaccinated with PCV7 or PCV13 previously should receive 
1–3 doses of PCV13, depending on their age at the time 
when vaccination begins and whether underlying medical 
conditions are present. Children aged 24–71 months with 
underlying medical conditions should receive 2 doses of 
PCV13 (Table 8). Interruption of the vaccination schedule 
does not require reinstitution of the entire series or the 
addition of extra doses.
Infants Aged 7–11 Months
Three doses are recommended. The first 2 doses should be •	
administered with an interval of at least 4 weeks between 
doses. The third dose should be administered at age 12–15 
months, at least 8 weeks after the second PCV13 dose.
Children Aged 12–23 Months
Two doses are recommended, with an interval of at least 8 •	
weeks between doses.
Children Aged >24 Months
Unvaccinated healthy children aged 24–59 months should •	
receive a single dose of PCV13.
Unvaccinated children aged 24–71 months with underly-•	
ing medical conditions (Table 2) should receive 2 doses 
of PCV13 with an interval of at least 8 weeks between 
doses.
Children Vaccinated Previously with 
PCV7 or PCV13
Incomplete PCV7/PCV13 Vaccination 
Children Aged <24 Months 
Infants and children aged <24 months who have received •	
≥1 dose of PCV7 should complete the vaccination series 
with PCV13 (Tables 9 and 10). 
Children aged 12–23 months who have received 3 doses of •	
PCV7 before age 12 months are recommended to receive 
1 dose of PCV13, administered at least 8 weeks after the 
most recent dose of PCV7 (Tables 9 and 10). This dose 
will constitute their fourth and final PCV dose, completing 
the series for the PCV7 serotypes and eliciting an immune 
response to the six additional serotypes. 
No additional PCV13 doses are recommended for children •	
aged 12–23 months who received 2–3 doses of PCV7 
before age 12 months and at least 1 dose of PCV13 at age 
≥12 months.
Children Aged >24 Months
Similar to the previous ACIP recommendation for use •	
of PCV7 (5), 1 dose of PCV13 is recommended for all 
healthy children aged 24–59 months with any incomplete 
PCV schedule (PCV7 or PCV13) before age 24 months 
(Table 11).
For children aged 24–71 months with underlying medical •	
conditions who have received any incomplete schedule of 
<3 doses of PCV (PCV7 or PCV13) before age 24 months, 
2 doses of PCV13 are recommended (Table 11). 
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For children with underlying medical conditions who have •	
received 3 doses of PCV (PCV7 or PCV13), a single dose 
of PCV13 is recommended through age 71 months. The 
minimum interval between doses is 8 weeks.
Complete PCV7 Vaccination
A single supplemental dose of PCV13 is recommended •	
for all children aged 14–59 months who have received 
4 doses of PCV7 or another age-appropriate, complete 
PCV7 schedule.
For children who have underlying medical conditions, a •	
single supplemental PCV13 dose is recommended through 
71 months. This includes children who have received 
PPSV23 previously. PCV13 should be administered at least 
8 weeks after the most recent dose of PCV7 or PPSV23. 
This will constitute the final dose of PCV for these children 
(Tables 9 and 11).
Children Aged 6–18 Years With 
Certain High-Risk Conditions
 A single dose of PCV13 may be administered for children •	
aged 6–18 years who have not received PCV13 previously 
and are at increased risk for invasive pneumococcal disease 
because of anatomic or functional asplenia, including 
sickle cell disease, immunocompromising conditions such 
as HIV-infection, cochlear implant, or cerebrospinal fluid 
leaks, regardless of whether they have previously received 
PCV7 or PPSV23.
Routine use of PCV13 is not recommended for healthy •	
children aged ≥5 years.
TABLE 9. Recommended schedule for administering doses of 13-valent pneumococcal conjugate vaccine (PCV13) to children aged <24 
months by PCV vaccination history and age — Advisory Committee on Immunization Practices, United States, 2010
Age at this visit  (mos)
Vaccination history: total number of PCV7 and/or PCV13 
doses received previously Recommended PCV13 regimen*
2–6 mos 0 doses 3 doses, 8 weeks apart; fourth dose at age 12–15 mos
1 dose 2 doses, 8 weeks apart; fourth dose at age 12–15 mos
2 doses 1 dose, 8 weeks after the most recent dose; fourth dose at age 12–15 mos
7–11 mos 0 doses 2 doses, 8 weeks apart; third dose at 12–15 mos
1 or 2 doses before age 7 mos 1 dose at age 7–11 mos, with a second dose at 12–15 mos, ≥8 weeks later
12–23 mos 0 doses 2 doses, ≥8 weeks apart
1 dose before age 12 mos 2 doses, ≥8 weeks apart
1 dose at ≥12 mos 1 dose, ≥8 weeks after the most recent dose† 
2 or 3 doses before age 12 mos 1 dose,≥8 weeks after the most recent dose† 
4 doses of PCV7 or other age-appropriate, 
complete PCV7 schedule
1 supplemental dose ≥8 weeks after the most recent dose
Abbreviation: PCV7 = 7-valent pneumococcal polysaccharide-protein conjugate vaccine.
* Minimum interval between doses is 8 weeks except for children vaccinated at age <1 year, for whom minimum interval between doses is 4 weeks.
† No additional PCV13 doses are indicated for children aged 12–23 months who have received 2 or 3 doses of PCV7 before age 12 months and at least 1 dose of PCV13 
at age ≥12 months.
TABLE 10. Recommended transition from 7-valent pneumococ-
cal polysaccharide-protein conjugate vaccine (PCV7) to 13-valent 
pneumococcal conjugate vaccine (PCV13) in the routine immuniza-
tion schedule among infants and children, according to number of 
previous PCV7 doses received
Infant series Booster dose
Supplemental 
PCV13 dose
2 mos 4 mos 6 mos ≥12 mos* 14–59 mos†
PCV7 PCV13 PCV13 PCV13 NA
PCV7 PCV7 PCV13 PCV13 NA
PCV7 PCV7 PCV7 PCV13 NA
PCV7 PCV7 PCV7 PCV7 PCV13
Abbreviation: NA = not applicable
* No additional PCV13 doses are indicated for children aged 12– 23 months who 
have received 2 or 3 doses of PCV7 before age 12 months and at least 1 dose 
of PCV13 at age ≥12 months.
† For children with underlying medical conditions (see Table 2), a supplemental 
PCV13 dose is recommended  through age 71 months.
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Administration of PPSV23 After PCV7 
or PCV13 Among Children Aged 
2–18 Years Who Are at Increased 
Risk for Pneumococcal Disease
Children aged ≥2 years with underlying medical condi-•	
tions (Table 2) should receive PPSV23 after completing all 
recommended doses of PCV13. These children should be 
administered 1 dose of PPSV23 at age ≥2 years and at least 
8 weeks after the most recent dose of PCV13 (Table 12). 
Children who have received PPSV23 previously also should •	
receive recommended PCV13 doses.
Children aged 24–71 months with underlying medical •	
conditions who received <3 doses of PCV7 before age 24 
months should receive a series of 2 doses of PCV13 followed 
by 1 dose of PPSV23 administered ≥8 weeks later.
Children aged 24–71 months with underlying medical •	
conditions who received any incomplete schedule of 3 
doses of PCV7 before age 24 months should receive 1 dose 
of PCV13 followed by 1 dose of PPSV23 administered ≥8 
weeks later.
When elective splenectomy, immunocompromising •	
therapy, or cochlear implant placement is being planned, 
PCV13 and/or PPSV23 vaccination should be completed 
at least 2 weeks before surgery or initiation of therapy. 
Revaccination With PPSV23 Among Children 
at Highest Risk 
A second dose of PPSV23 is recommended 5 years after •	
the first dose of PPSV23 for children who have anatomic 
or functional asplenia, including SCD, HIV infection, or 
other immunocompromising condition (Table 12). No 
more than 2 PPSV23 doses are recommended. 
American Indian/Alaska native Children
Routine use of PPSV23 after PCV7 or PCV13 is not rec-•	
ommended for American Indian/Alaska Native children 
aged ≥24 months without underlying medical conditions. 
However, in special situations, public health authorities 
might recommend use of PPSV23 after PCV7 or PCV13 
for American Indian/Alaska Native children who are living 
in areas/communities in which risk for invasive pneumococ-
cal disease is increased.
Public Health Considerations
Evaluation of PCV13 Cost-
Effectiveness
Two independent analyses of PCV13 cost-effectiveness 
reviewed according to ACIP guidelines were presented for 
consideration by ACIP (82,83). Although these studies used 
different modeling approaches and assumptions about poten-
tial vaccine effects, their conclusions were largely consistent 
with each other. A CDC study using a cohort model to 
evaluate cost-effectiveness among infants and young children 
did not include the potential indirect PCV13 effects among 
unvaccinated groups in the analysis because of uncertainty 
regarding their magnitude and timing and the fact that vary-
ing assumptions about indirect effects were demonstrated to 
have major impact on PCV7 cost-effectiveness estimates (84). 
The results suggested that from a societal perspective, routine 
TABLE 11. Recommended schedule for administering doses of 13-valent pneumococcal conjugate vaccine (PCV13) to children aged ≥24 
months by PCV vaccination history and age 
Age at this visit (mos)
Vaccination history: total number of PCV7 and/
or PCV13 doses received previously before age 24 
months Recommended PCV13 regimen*
24–59 mos in healthy children Unvaccinated or any incomplete schedule 1 dose, ≥ 8 weeks after the most recent dose
4 doses of PCV7 or other age-appropriate, complete 
PCV7 schedule
1 supplemental dose, ≥8 weeks after the most recent dose
24–71 mos in children with 
underlying medical conditions†
Unvaccinated or any incomplete schedule of <3 doses 2 doses, the first dose ≥8 weeks after the most recent dose and a 
second dose ≥ 8 weeks later
Any incomplete schedule of 3 doses 1 dose, ≥ 8 weeks after the most recent dose
4 doses of PCV7 or other age-appropriate complete 
PCV7 schedule
1 supplemental dose, ≥8 weeks after the most recent dose
Abbreviation: PCV7 = 7-valent pneumococcal polysaccharide-protein conjugate vaccine.
* Minimum interval between doses is 8 weeks.
† For list of conditions, see Table 2.
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infant vaccination of a single birth cohort with PCV13 replac-
ing PCV7 was likely cost-saving with over $142 million saved 
including productivity gains (82). The 1-dose supplemental 
PCV13 vaccination was determined to be comparable in 
cost-effectiveness to other accepted public health interven-
tions, costing approximately $20,200 per discounted quality 
adjusted life-year (QALY) saved (range in sensitivity analyses: 
$11,200–$35,500 per discounted QALY saved). Another study 
sponsored by the PCV13 manufacturer used a decision-analytic 
Markov model that also predicted substantial net savings for 
the routine PCV13 program compared with PCV7 (83). The 
1-dose supplemental PCV13 program was found to be cost-
saving under the assumption that the occurrence of indirect 
effects would be accelerated by ≥6 months as the supplemental 
dose would reduce nasopharyngeal carriage of certain PCV13 
serotypes among older children; when indirect effects were not 
included, the supplemental dose program was still considered 
cost-effective.
 Postlicensure Monitoring
Because PCV13 was licensed by FDA on the basis of 
safety and immunogenicity studies alone, without efficacy 
data, postlicensure monitoring of vaccine effectiveness will be 
particularly important in addition to the usual postlicensure 
monitoring of safety. Also, because wide use of PCV13 can be 
expected to alter the distribution of S. pneumoniae serotypes, 
continued monitoring of the epidemiologic patterns of pneu-
mococcal disease will remain necessary (85). FDA and CDC 
will conduct postlicensure monitoring for adverse events associ-
ated with PCV13 using VAERS data and CDC will conduct 
a case-control study of vaccine effectiveness using ABCs data; 
the manufacturer will also conduct postlicensure studies. 
 In June 2009, the Council of State and Territorial 
Epidemiologists adopted a new position statement and case 
definition for national surveillance of IPD and recommended 
enhanced surveillance to track the effects of PCV13 vaccination 
program (86). Cases of IPD among all ages are now reportable 
in many states, and health departments in these states forward 
the data to CDC through the National Notifiable Diseases 
Surveillance System. The national surveillance case definition 
for invasive S. pneumoniae disease is isolation of S. pneumoniae 
from a normally sterile body site (e.g., blood, cerebrospinal 
fluid, or, less commonly, joint, pleural or pericardial fluid). 
Epidemiologically important data (e.g., demographics, infor-
mation on underlying conditions associated with increased risk 
of IPD, vaccination status, and antibiotic susceptibility testing 
results) should be reported for each case to track prevalence and 
geographic distribution of antibiotic resistance patterns.
In addition, public health officials might want to track 
changes in serotypes among IPD cases in their jurisdiction. A 
method for polymerase chain reaction (PCR)-based serotyp-
ing of S. pneumoniae isolates is now available for use by state 
and territorial public health laboratories. The PCR method 
or conventional serotyping can be used for distinguishing 
whether the detected cases are caused by serotypes included 
in PCV13 (87,88).
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